Vasospastic phenomena in patients treated with beta-adrenoceptor blocking agents

Area of Science:

• Pharmacology
• Cardiology
• Vascular Medicine

Background:

• Beta-adrenoceptor blocking agents are widely used for cardiovascular conditions.
• Raynaud's phenomenon, characterized by vasospastic episodes, can be a side effect of certain medications.
• The exact mechanism underlying drug-induced Raynaud's phenomenon remains unclear.

Purpose of the Study:

• To investigate the occurrence of Raynaud's phenomenon in patients treated with beta-adrenoceptor blocking agents.
• To explore the potential pathogenetic mechanisms of beta-blocker-induced Raynaud's phenomenon.
• To provide recommendations for the prescription of beta-blocking drugs in at-risk populations.

Main Methods:

• Observational study involving 21 patients who developed Raynaud's phenomenon during beta-blocker therapy.
• Analysis of clinical data to establish the relationship between drug treatment and vasospastic symptoms.
• Preliminary investigation into potential pathogenetic mechanisms, including cardiac output and adrenergic activity.

Main Results:

• Twenty-one patients exhibited Raynaud's phenomenon clearly linked to beta-blocker treatment.
• Symptoms occurred with both cardioselective and non-selective beta-blocking agents.
• Preliminary data suggest alpha-adrenergic dominance in peripheral circulation as a more probable cause than decreased cardiac output.

Conclusions:

• Beta-blocker therapy can induce Raynaud's phenomenon through mechanisms potentially involving alpha-adrenergic dominance.
• Vasospastic symptoms are associated with various types of beta-blocking agents.
• Caution is advised when prescribing beta-blockers to individuals with pre-existing peripheral vascular disease.